Clinical trials: Head and Neck Cancer Patients
Oropharyngeal Dysphagia
REVIVE Prospective Registry Cohort Study
The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.
- Trial name
- NCT07429890
- Testing
- Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention.
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of California, Davis
Nasopharyngeal Carcinoma, Liver Metastases
Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases
The goal of this clinical trial is to learn about hepatectomy on the prognosis of patients with nasopharyngeal carcinoma liver metastases (NCLM).
- Trial name
- NCT05771025
- Testing
- Hepatectomy
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Head and Neck Cancer
Head and Neck Early Relapse Detection Study (HERD)
Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with an annual incidence of 12000 cases in the UK alone. More than 60% of cases are diagnosed at the locally advanced stage.
- Trial name
- HERD (NCT05097625)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- University College, London
Radiation Dermatitis, Head and Neck Cancer
Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients
to develop a deep learning-based model to grade the severity of radiation dermatitis (RD) and predict the severity of radiation dermatitis in patients with head and neck cancer undergoing radiotherapy, so as to provide support…
- Trial name
- NCT05607225
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Cancer
Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx
RATIONALE: Studying the proteins expressed in samples of tumor tissue from patients with cancer may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00899340
- Testing
- gene expression analysis, microarray analysis, protein expression analysis
- Volunteers
- 54 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical adjuvant therapy in treatment naïve…
- Conditions
- Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx
- Trial name
- NCT03737968
- Testing
- Durvalumab, durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yonsei University
EGFR Positive Solid Tumors
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
- Trial name
- NCT01963715
- Testing
- IMGN289
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- ImmunoGen, Inc.
Esophageal Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and…
- Trial name
- NCT00060268
- Testing
- HPPH
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Cancer
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00425750
- Testing
- bortezomib, docetaxel, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Radiotherapy-induced Oral Mucositis
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
Evaluate the effectiveness and safety of traditional Chinese medicine compound in improving radiotherapy-induced oral mucositis in patients with head and neck malignant tumors.
- Trial name
- NCT07339774
- Testing
- Zishui Daohuo oral liquid combined with Kujiu mouthwash, Radiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- West China Hospital
Esophageal Cancer
MR/PET in the Evaluation of Patients With Esophageal Cancer
In this prospective study, we will recruit newly diagnosed esophageal cancer patients and perform MR/PET before and after chemoradiation therapy.
- Trial name
- NCT02547610
- Testing
- The imaging biomarkers determined by MR-PET
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Carcinoma
Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention
To study the difference in the proportion of patients with nasopharyngeal carcinoma who lost more than 10% of their body weight within 1 month after radiotherapy and chemotherapy using the mobile platform for whole-process…
- Trial name
- NCT05834712
- Testing
- mobile platform or not mobile platform
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor…
- Trial name
- NCT00290719
- Testing
- cisplatin, gefitinib, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Head and Neck Cancer
Pre-habilitation of Patients With Head and Neck Cancer
The purpose of this study is to explore whether early initiated physical exercise concurrent with a swallowing and mouth opening exercise program will have a positive effect on swallowing function and other quality of life…
- Trial name
- SYNK (NCT02385929)
- Testing
- Swallowing therapy & resistance training
- Where
- 2 sites in Denmark
- Volunteers
- 240 people
- Sponsor
- Irene Wessel
Head and Neck Cancer
Goal Directed Fluid Therapy in Free Flap Reconstructive Surgery
Wide excision of head and neck cancer with microsurgical free flap's reconstruction (FFR) results to a high cancer cure rate and a good functional recovery.
- Trial name
- NCT01129037
- Testing
- Goal directed fluid management based on continuous monitoring of stroke volume
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- University Health Network, Toronto
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
Carcinoma, Squamous Cell
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
The purpose of this study is to collect data and evaluate how the tumor is broken down in response to standard of care cetuximab treatment by evaluating the FDG-PET/CT scans, toxicity, see how well the FDG-PET/CT scans predict…
- Trial name
- SCCHN (NCT00671437)
- Testing
- FDG-PET/CT, Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Gastrointestinal Cancer, Colorectal Cancer
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
- Conditions
- Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer
- Trial name
- NCT04077372
- Testing
- Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Head and Neck Carcinoma
Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients
This phase II trial compares different pain management interventions (standard of care [SOC], neurofeedback [NFB] training, and compassionate high alert team [CHAT]) in patients diagnosed with head and neck cancer who are at risk…
- Trial name
- NCT05077072
- Testing
- Best Practice, Counseling, Electroencephalography
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Cancer
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy .
- Trial name
- NIVONASO-21 (NCT04875611)
- Testing
- Opdivo
- Where
- 4 sites in Poland
- Volunteers
- 32 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.